Vartis, and Sanofi. TW has received travel assistance from Novartis and Sanofi and study funding from Novartis and AstraZeneca. None of your other authors has any personal or monetary conflict of interest to declare. AUTHOR CONTRIBUTIONS XW and CC have been involved in information collection and interpretation, statistical analysis, and writing of the manuscript; CX and WH had been involved in information evaluation and interpretation, and reviewing on the manuscript. RLY, KLJ, MH, and CKR had been involved in conception and design of the study, data interpretation, and reviewing of your manuscript. TW and ZS were involved in conception and style in the study, information interpretation, statistical analysis and drafting of the manuscript, and are guarantors of this perform. P EE R R EV I E W The peer assessment history for this short article is readily available at publons. com/publon/10.1111/dom.14683. Information AVAI LAB ILITY S TATEMENT The datasets generated during and/or analyzed through the existing study will not be publicly accessible but are available from the corresponding authors on reasonable request. ORCID Karen L. Jones Tongzhi Wu orcid.org/0000-0002-1155-5816 orcid.org/0000-0002-5527-256X orcid.org/0000-0003-1656-9210 Christopher K. RaynerRE FE RE NCE S1. Ahmad TR, Haeusler RA. Bile acids in glucose metabolism and insulin signalling – mechanisms and study requires. Nat Rev Endocrinol. 2019; 15(12):701-712. 2. Garcia-Canaveras JC, Donato MT, Castell JV, Lahoz A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat making use of a UPLC-MRM-MS-validated technique. J Lipid Res. 2012;53(ten): 2231-2241. 3. Xie C, Huang W, Young RL, et al. Role of bile acids within the regulation of meals intake, and their dysregulation in metabolic disease. Nutrients. 2021;13(4):1104. four. Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic issues. Prog Lipid Res.Natural Product Like Compound Library Autophagy 2021;82: 101094. 5. Ge X, Yin L, Ma H, Li T, Chiang JY, Zhang Y. Aldo-keto reductase 1B7 is actually a target gene of FXR and regulates lipid and glucose homeostasis. J Lipid Res. 2011;52(eight):1561-1568. six. Shin DJ, Wang L. Bile acid-activated receptors: a overview on FXR and other nuclear receptors.MIM1 In Vivo Handb Exp Pharmacol.PMID:35991869 2019;256:51-72. 7. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167-177. eight. Brighton CA, Rievaj J, Kuhre RE, et al. Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors. Endocrinology. 2015;156(11):3961-3970. 9. Xie C, Jones KL, Rayner CK, Wu T. Enteroendocrine hormone secretion and metabolic handle: value in the area on the gut stimulation. Pharmaceutics. 2020;12(9):790. ten. Wu T, Rayner CK, Horowitz M. Incretins. Handb Exp Pharmacol. 2016; 233:137-171. 11. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthier humans. J Clin Endocrinol Metab. 2013;98(four):E718-E722. 12. Albaugh VL, Banan B, Antoun J, et al. Role of bile acids and GLP-1 in mediating the metabolic improvements of bariatric surgery. Gastroenterology. 2019;156(4):1041-1051. 13. Harris LA, Kayser BD, Cefalo C, et al. Biliopancreatic diversion induces higher metabolic improvement than Roux-en-Y gastric bypass. Cell Metab. 2019;30(5):855-864. 14. Calderon G, McRae A, Rievaj J, et al. Ileo-colonic delivery of conjugated bile acids.
